Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


COVID-19 Will Spur Decentralized and Hybrid Trials – Novartis Hails Digital Investment

The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.

Coronavirus COVID-19 Clinical Trials Research & Development

Circassia Ends AZ Deal To Dig Itself Out Of Debt Hole

Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.

Companies Deals Respiratory

Daiichi Sankyo Enters Europe's Cholesterol Market

The Japan-headquartered drugmaker says there is a need for affordable oral treatment options on top of currently available lipid-lowering therapies and the two drugs it licensed from Esperion can meet that need.

Cardiovascular Approvals Market Access

Coronavirus Spotlight

COVID-19 Lock-Down: India Pharma Manufacturing Limps Along Amid Challenges

Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.

Commercial Coronavirus COVID-19

Rolling Coverage Of The Coronavirus Outbreak And The Biopharma Industry's Response Is Here.


 Recent Tweets from Scrip


Coronavirus 2019-nCov novel coronavirus concept resposible for asian flu outbreak and coronaviruses influenza as dangerous flu strain cases as a pandemic 3d rendering

COVID-19 Pipeline Tracker

Product candidates in development worldwide to address the 2019-nCoV pandemic, categorized by treatment and prevention. Subscription required.

View Tracker

 

Commercial Explore this Topic

Set Alert for Commercial

Pfizer and BioNTech To Initiate COVID-19 Vaccine Clinical Trials In April

The two companies announced more details about their COVID-19 vaccine development plan, including a $185m upfront payment and $113m equity investment from Pfizer.

Deals Coronavirus COVID-19

Cash-Rich PureTech Displays Resilience In Troubled Times

PureTech said it finished 2019 with healthy finances and a promising pipeline which analysts said should offer positive catalysts for the UK group’s stock in 2020.

Commercial Companies

CSL Behring And SAB Explore Polyclonal Antibodies For COVID-19

CSL Behring is backing the US biotech SAB Biotherapeutics in developing polyclonal antibodies in cattle for their efficacy against the pandemic virus, adding a second strand to the research efforts of the blood products specialty company.

Coronavirus COVID-19 Deals

Purple Patch: US Approval For Cipla's Gx Albuterol, Staggered Supplies Planned

Cipla gets US FDA go-ahead earlier than anticipated for first generic of Merck’s Proventil, setting the stage for increased competition in the albuterol segment, where demand is up amid the coronavirus pandemic.

Commercial Generic Drugs

COVID-19 Lock-Down: India Pharma Manufacturing Limps Along Amid Challenges

Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.

Commercial Coronavirus COVID-19

Arrakis Inks First Partnership In RNA-Targeted Collaboration With Roche

Biotech gets $190m up front in partnership that will discover small molecule RNA-targeted therapies against a range of targets selected by Roche. Arrakis thinks its technology can drug difficult-to-reach targets.

Deals Business Strategies
See All

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

US FDA Extends Roche’s Risdiplam Decision Date

The submission of more trial data from Roche has prompted the US FDA to extend by three months its decision on whether to approve risdiplam for spinal muscular atrophy.  

Companies Market Access

India Keeps Door Ajar For Hydroxychloroquine Exports, Drug Makers Geared Up

Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.

Policy & Regulation India

Amarin's Vascepa May Face Generic Competition In US Next Year After Patents Ruled Invalid

Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.

Legal Issues Intellectual Property
See All

Research & Development Explore this Topic

Set Alert for Research & Development

Cash-Rich PureTech Displays Resilience In Troubled Times

PureTech said it finished 2019 with healthy finances and a promising pipeline which analysts said should offer positive catalysts for the UK group’s stock in 2020.

Commercial Companies

IIL-Griffith Univ Readying Reasonably Priced COVID-19 Vaccine

The entry of India’s state-owned Indian Immunologicals and partner Griffith University in the COVID-19 vaccine race could potentially disrupt pricing dynamics. The alliance is developing a live-attenuated, single dose vaccine, which it hopes will be ready for launch in 18-24 months.

Research & Development Coronavirus COVID-19

'Peoples' Hope' Remdesivir Results Due Soon - What To Look For?

The first data readout for remdesivir, the much anticipated antiviral for the coronavirus pandemic, is expected in days. Scrip surveys antiviral development and regulatory experts to gauge their interest and the key aspects to watch for in the milestone announcement.

Coronavirus COVID-19 Clinical Trials
See All
UsernamePublicRestriction

Register